Pharma China (www.pharmachinaonline.com) is the most influential English media and source of business intelligence covering the Chinese pharmaceutical sector. Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China’s burgeoning but increasingly complex healthcare marketplace, and is subscribed by most MNC pharma companies, leading CROs, investment banks, consulting firms active in China as well as relevant industry associations and government agencies.

Note: To view full text of free articles, you need to register as a basic member first and then log in. To view premium articles, you need to subscribe to Pharma China as a premium member. For more information or subscription, please contact info@pharmachinaonline.com. If you wish to unsubscribe from this e-Alert, please reply this e-mail with "Remove" in the subject line.
Editor´s Picks
China's New Cybersecurity Law And Draft Data Localization Measures Expected To Burden Multinational Companies(6/22/2017 )  (Premium)
  This White Paper from legal experts of Jones Day, which is published on Mondaq, provides an overview of the new compliance obligations the new Law imposes and also takes a close look at the draft Measures giving guidance on the data localization requirements.
The Market
Analysis: New Product Additions of 2017 NRDL(6/20/2017 )  (Premium)
  By number of Western medicine (WM) products newly added to the 2017 NRDL, cardiovascular system, metabolism, blood and blood making system and antineoplastic drugs are among the highest ranking therapeutic categories (TCs), according to QuintilesIMS.
Industry News
China's Innovative Medical Withdraws from Investment Deal with Pluristem Therapeutics(6/22/2017 )  (Premium)
  Stem cell company Pluristem Therapeutics Ltd. (Nasdaq:PSTI; TASE: PLTR) announced on June 21 that Chinese company Innovative Medical, which was to have invested $30 million in Pluristem, had withdrawn from the deal. A delay in completing the deal, signed in October, was reported in December.
Chinese Development Zone and Pakistani University Sign MOU for Drug R&D Collaboration(6/21/2017 )  (free)
  National Economic and Technical Development Zone in Liuyang, Hunan Province, China (NETDZLY) signed MoU with International Centre for Chemical and Biological Sciences (ICCBS), University of Karachi (UoK) on June 21.
Snapshot: Bayer's Urban Hospital Drug Sales Witness 10% Growth in 2016(6/20/2017 )  (Premium)
  Bayer¡¯s drug sales in urban hospitals of major Chinese cities is projected to be nearly CNY 2,984 million in 2016, up only 10.23% year on year, according to the PDB database of the China Pharmaceutical Industry Information Center (CPIIC).
Sanofi to e-Market Consumer Healthcare Products to the Chinese from Australia(6/20/2017 )  (Premium)
  Sanofi Consumer Healthcare Australia, a division of the global health giant Sanofi, will offer its Ostelin and Cenovis brands to Chinese consumers on Netease Kaola. Netease Kaola is the country's largest self-purchasing e-commerce platform in China.
ShangPharma Announces Second Milestone in Move for Chinese Stock Listing(6/20/2017 )  (free)
  ShangPharma announced on June 19 the intent to join with Quantum Hi-Tech China Bio which announced earlier their intent to purchase Shanghai ChemPartner, ShangPharma's CRO/CMO subsidiary.
Regulatory News
CDE Publicizes Batch 20 of Drug Applications To Be Granted Priority Review Status(6/20/2017 )  (Premium)
  The Center for Drug Evaluation (CDE) under the CFDA publicized on June 20 a new list of two drug applications (by application number) (20th Batch) which are to be granted priority review status.
CFDA Announces Officially Joining the ICH(6/19/2017 )  (Premium)
  The CFDA announced on June 19 that the International Council for Harmonization (ICH) met in Montreal, Canada from May 31 to June 1, 2017 and approved the China Food and Drug Administration (CFDA) as a new Regulatory Member.
General Health
Central Government to Support More than 600 Healthcare Institutions(6/21/2017 )  (Premium)
  The NDRC recently issued a notice on the investment plan under central government budgetary spending in the health and family planning sector this year.Among the total, CNY 13.4 billion or 55.8% will be invested in infrastructural building projects of county hospitals.
China Establishes National Center for Children's Health(6/20/2017 )  (Premium)
  The center will focus on treatment of complicated illnesses and training of pediatricians to meet rising demand. It will also function as a data collection center on major illnesses affecting children in China and an epidemic monitoring and research body.
Product/R&D News
Chi-Med Initiates a Phase I/II Clinical Trial of Novel FGFR Inhibitor HMPL-453 in China(6/22/2017 )  (Premium)
  Hutchison China MediTech Limited (Chi-Med) (AIM/Nasdaq: HCM) has just initiated a Phase I/II clinical trial of HMPL-453 in China. HMPL-453 is a novel, highly selective and potent small molecule inhibitor targeting fibroblast growth factor receptor (FGFR).
API/Bulk Drug News
Another Chinese API Producer in Data Integrity Mudpool and on U.S. Import Alert(6/22/2017 )  (Premium)
  The FDA released a warning letter sent to Chinese API maker Qinhuangdao Zizhu Pharmaceutical in April that outlined data integrity problems at the company¡¯s Hebei province facility following an inspection late last year.
People in the News
Recent Executive Moves(6/22/2017 )  (Premium)
  Recent Chinese pharma-related executive movements at companies including Merck KGaA China, OIRC Pharma, Nobel Biocare, BMS China and Novartis China.
Top News Worldwide
White House Task Force Echoes Pharma Proposals(6/21/2017 )  (Premium)
  The top priority among all is extending the patent life of drugs in foreign markets to ¡°provide for protection and enforcement of intellectual property rights.¡± This will ensure ¡°that American consumers do not unfairly subsidize research and development for people throughout the globe.¡±
© Wicon International Group¡¡Support by: www.heightow.com Home | Site map | Contact Us | Links